Q3: 2025-11-06 Earnings Summary
EPS of $0.00 misses by $0.01
| Revenue of $20.59M (-6.28% Y/Y) beats by $591.00K
Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST
Company Participants
John Duke – President, CEO & Director
Mark Frost – Interim CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Conference Call Participants
Taylor Krafchik
Lucas Baranowski – KeyBanc Capital Markets Inc., Research Division
Bruce Jackson – The Benchmark Company, LLC, Research Division
Presentation
Operator
Good day, and welcome to the Third Quarter 2025 Harvard Bioscience Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Taylor Krafchik, Senior Vice President at Ellipsis TA. Please go ahead.
Taylor Krafchik
Thank you, operator, and good morning, everyone. Thank you for joining the Harvard Bioscience Third Quarter 2025 Earnings Conference Call. Leading the call today will be John Duke, President and Chief Executive Officer; and Mark Frost, Interim Chief Financial Officer. In conjunction with today’s recorded call, we have provided a presentation that will be referenced during our remarks that is posted to the Investor Relations section of our website at investor.harvardbioscience.com.
Please note that statements made in today’s discussion that are not historical facts, including statements on management’s expectations of future events or future financial performance are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience’s management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today’s press release, the Harvard Bioscience Form 10-Q and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties and contingencies associated therewith.
During the call, management will also reference certain non-GAAP
Read the full article here